Yeztugo's HIV Prevention Shot: Progress & Challenges

Gileads Yeztugo, a twice-yearly HIV prevention shot, has seen over nine thousand prescriptions since launch, but faces challenges from insurance gaps, high costs, and preference for daily pills. Despite potential to revolutionize PrEP, Yeztugos adoption is slower than expected, with only seventy-five patients at one New York clinic. Insurance covers it for most plans, but often with copays or deductibles. Yeztugos sales potential is significant, but its success hinges on overcoming these hurdles. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c961a743ed19bc8b